Welcome!

News Feed Item

Analysis of the US Retinal Therapeutics Market

NEW YORK, Jan. 7, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Analysis of the US Retinal Therapeutics Market
http://www.reportlinker.com/p01936265/Analysis-of-the-US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Improvements in Administration and Efficacy Drive Growth

Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.

Methodology

•The information contained in this research service was derived from a variety of relevant primary and secondary sources.
•Secondary data sources include company publications (annual reports, US Securities and Exchange Commission (SEC) filings, investor presentations, earnings transcripts, and press releases); US government public sources (clinicaltrials.gov, FDA.gov, Orange Book); pharmaceutical industry databases; and published articles in scientific and medical journals.
•Revenue forecasting is performed using a robust, data-driven, bottom-up, patient-based approach. Marketed drugs and potential new entrants in Phase 3 of development and beyond are individually forecast, and aggregate figures are provided.
•Revenue from off-label usage is not included, but is accounted for in forecast models.

Key Findings

Current Market Landscape
•Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) due to their high efficacy and safety.
•By 2017, Genentech and Regeneron are expected to split the AMD, DME, and RVO segments with their VEGF inhibitors Lucentis and Eylea, respectively.
- In 2017, Lucentis and Eylea are each estimated to produce roughly $Xbillion in revenue.
- Eylea's favorable bi-monthly dosing has enabled Regeneron to be a viable competitor to Genentech's Lucentis. In 2014, Eylea's label will expand to include DME.
•Eylea and Lucentis are comparably priced; however, Avastin is available through compounding pharmacies at an immense discount, which significantly disrupts the branded AMD, DME, and RVO market. X to X% of the AMD, DME, and RVO segments are estimated to be off-label Avastin usage.
•Although new VEGF treatments are highly efficacious, they require intravitreal injections which is an invasive procedure. Thus, dosing frequency is a key determinant of market uptake.
•The AMD, DME, and RVO segments are set for continued growth due to an aging US population, and the DME segment in particular due to an increasing prevalence of diabetes.

Future Competitors
•There are more than 15 compounds in Phase 2 development and beyond.
•If approved, Allergan will have the first once-every-3-months VEGF inhibitor with AGN-150998, expected to launch in 2018 to 2019.
- If Phase 3 data shows comparable efficacy and safety to current VEGF inhibitors, Allergan has the potential to gain X% or more of the market due to its less frequent dosing.
•Ophthotec's platelet-derived growth factor (PDGF) inhibitor Fovista has the potential to become the first add-on therapy to VEGF inhibitors.
- This product has significant market potential due to a complementary rather than competitive add-on therapy strategy.
•New treatments that can be administered orally or topical drops would revolutionize treatment; however, it appears unlikely that any current pipeline medications will have comparable safety and efficacy profiles to current VEGF treatments.

Scope and Segmentation

Geographic Coverage: US
Study Period: 2009–2017
Base Year: 2012
Forecast Period: 2013–2017
Monetary Unit: US Dollars

•This research service evaluates the United States market for pharmaceutical treatments for the following retinal diseases: AMD, DME, and RVO.
•Units are defined as patients. Treated patient numbers, when estimated, are derived from annual sales revenue and annual cost of therapy.
•The price is the annual cost of therapy, and the average annual cost of therapy is based on the average wholesale price (AWP) per drug, as reported in Thomson Reuters Red Book. Hospital or clinic-associated expenses are not included in the cost of therapy.
•Indication-specific annual revenue, as reported, is used when available. Otherwise, estimates are used.

Key Questions This Study Will Answer

Is the market growing, how long will it continue to grow, and at what rate?
Are the existing competitors structured correctly to meet customer needs?
What pipeline candidates have the greatest potential? When are they expected to reach market?
Which treatments are set to dominate the market? How much market share for each competitor?
What is the peak sales potential for AMD, DME, and RVO market?
What the strengths and weaknesses of current and future therapies?

Table Of Contents

1. Executive Summary
2. Market Overview
3. Competitive Playbook
4. Total Retinal Therapeutics Market
• Drivers and Restraints
• Forecasts and Trends
5. Competitive Environment
6. AMD Segment Breakdown
7. DME Segment Breakdown
8. RVO Segment Breakdown
9. Key Companies to Watch
10. The Last Word
11. Appendix

List of Exhibits

• Total Retinal Therapeutics Market: Market Engineering Measurements, US, 2012
• Total Retinal Therapeutics Market: Market Segmentation, US, 2012
• Total Retinal Therapeutics Market: Game-changing Strategies, US, 2013
• Total Retinal Therapeutics Market: Key Market Drivers, US, 2012–2017
• Total Retinal Therapeutics Market: Key Market Restraints, US, 2012–2017
• Total Retinal Therapeutics Market: Market Engineering Measurements, US, 2012
• Total Retinal Therapeutics Market: Revenue Forecast, US, 2009–2017
• Total Retinal Therapeutics Market: Average Wholesale Price per Injection, US, 2009–2017
• Total Retinal Therapeutics Market: Competitive Landscape, US, 2013
• Total Retinal Therapeutics Market: Marketed Product Analysis, US, 2013
• Total Retinal Therapeutics Market: Pipeline Analysis, US, 2013
• Total Retinal Therapeutics Market: Absolute Market Share Trend by Revenue US, 2012 and 2017
• Total Retinal Therapeutics Market: Company Market Share Analysis of Top 4 Participants, US, 2012
• Total Retinal Therapeutics Market: SWOT Analysis, US, 2013
• Total Retinal Therapeutics Market: Timeline of Key Events, US, 2009–2017
• Total Retinal Therapeutics Market: Patent Expirations, US, 2000–2030
• Total Retinal Therapeutics Market, AMD Segment: Comparative Best Corrected Visual Acuity from Baseline for Select Marketed Drugs, US, 2012
• AMD Segment: Market Engineering Measurements, US, 2012
• AMD Segment: Revenue Forecast, US, 2009–2017
• AMD Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• AMD Segment: Penetration Analysis, US, 2009–2017
• DME Segment: Market Engineering Measurements, US, 2012
• DME Segment: Revenue Forecast, US, 2009–2017
• DME Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• DME Segment: Penetration Analysis, US, 2009–2017
• RVO Segment: Market Engineering Measurements, US, 2012
• RVO Segment: Revenue Forecast, US, 2009–2017
• RVO Segment: Prevalence and Treated Patient Forecast, US, 2009–2017
• RVO Segment: Penetration Analysis, US, 2009–2017

To order this report: Analysis of the US Retinal Therapeutics Market
http://www.reportlinker.com/p01936265/Analysis-of-the-US-Retinal-Therapeutics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
SYS-CON Events announced today that FalconStor Software® Inc., a 15-year innovator of software-defined storage solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. FalconStor Software®, Inc. (NASDAQ: FALC) is a leading software-defined storage company offering a converged, hardware-agnostic, software-defined storage and data services platform. Its flagship solution FreeStor®, utilizes a horizonta...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 ad...
SYS-CON Events announced today that (ISC)²® (“ISC-squared”) will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Two leading non-profits focused on cloud and information security, (ISC)² and Cloud Security Alliance (CSA), developed the Certified Cloud Security Professional (CCSP) certification to address the increased demand for cloud security expertise due to rapid growth in cloud. Recently named “The Next...
The Art of DevOps provides a fun overview to help teams understand DevOps. Written in the style of the famous 6th century Chinese manuscript “The Art of War,” this eBook describes DevOps in the form of a mission to continuously deliver assets to the operational battlegrounds safely, securely, and quickly. It’s a fun read with valuable insights.
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
The Quantified Economy represents the total global addressable market (TAM) for IoT that, according to a recent IDC report, will grow to an unprecedented $1.3 trillion by 2019. With this the third wave of the Internet-global proliferation of connected devices, appliances and sensors is poised to take off in 2016. In his session at @ThingsExpo, David McLauchlan, CEO and co-founder of Buddy Platform, will discuss how the ability to access and analyze the massive volume of streaming data from mil...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, will give users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion w...
WebSocket is effectively a persistent and fat pipe that is compatible with a standard web infrastructure; a "TCP for the Web." If you think of WebSocket in this light, there are other more hugely interesting applications of WebSocket than just simply sending data to a browser. In his session at 18th Cloud Expo, Frank Greco, Director of Technology for Kaazing Corporation, will compare other modern web connectivity methods such as HTTP/2, HTTP Streaming, Server-Sent Events and new W3C event APIs ...
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies adopt disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advanced analytics, and DevO...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Avere delivers a more modern architectural approach to storage that doesn’t require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbuilding of data centers ...
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...